Zealand Pharma A/S (OTCMKTS:ZLDPF) Reaches New 1-Year Low - Here's What Happened

Key Points

• Zealand Pharma A/S has reached a new 52-week low of $54.11, marking an 11.4% decline from its previous close of $61.06.
• Despite recent stock declines, analysts are optimistic, with multiple firms upgrading the stock to a "strong-buy" rating, leading to a consensus rating of "Strong Buy".
• The company reported earnings of ($0.67) per share in its last quarter, surpassing expectations but with a significant revenue miss, bringing in only $1.14 million against estimates of $248.61 million.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) shares reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $54.11 and last traded at $54.11, with a volume of 150 shares. The stock had previously closed at $61.06.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ZLDPF. Barclays upgraded shares of Zealand Pharma A/S to a "strong-buy" rating in a research note on Monday, July 7th. Wells Fargo & Company raised Zealand Pharma A/S to a "strong-buy" rating in a research report on Thursday, July 24th. Finally, BNP Paribas raised shares of Zealand Pharma A/S to a "strong-buy" rating in a research report on Tuesday, July 1st. One analyst has rated the stock with a buy rating and five have assigned a strong buy rating to the stock. According to data from MarketBeat, Zealand Pharma A/S presently has an average rating of "Strong Buy".

Zealand Pharma A/S Stock Performance

The stock has a market capitalization of $3.75 billion, a P/E ratio of -21.19 and a beta of 0.68. The company has a quick ratio of 25.07, a current ratio of 25.10 and a debt-to-equity ratio of 0.03. The company has a 50-day moving average price of $61.62 and a two-hundred day moving average price of $74.83.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.67) EPS for the quarter, beating analysts' consensus estimates of ($0.77) by $0.10. Zealand Pharma A/S had a negative net margin of 2,127.09% and a negative return on equity of 13.40%. The firm had revenue of $1.14 million during the quarter, compared to analyst estimates of $248.61 million. Equities analysts expect that Zealand Pharma A/S will post -2.19 earnings per share for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.